Search

Your search keyword '"Cumhur Adiay"' showing total 6 results
Start Over Author "Cumhur Adiay"
6 results on '"Cumhur Adiay"'

1. Immunogenicity and protection efficacy of a COVID-19 DNA vaccine encoding spike protein with D614G mutation and optimization of large-scale DNA vaccine production

Author

Aytül Gül, Sedef Erkunt Alak, Hüseyin Can, Muhammet Karakavuk, Gülay Korukluoğlu, Ayşe Başak Altaş, Ceren Gül, Tuğba Karakavuk, Ahmet Efe Köseoğlu, Hivda Ülbeği Polat, Hilal Yazıcı Malkoçoğlu, Arzu Taş Ekiz, İrem Abacı, Özge Aksoy, Hakan Enül, Cumhur Adıay, Serdar Uzar, Fahriye Saraç, Cemal Ün, Adnan Yüksel Gürüz, Ayşe Gülten Kantarcı, Hasan Akbaba, Gülşah Erel Akbaba, Habibe Yılmaz, Aysu Değirmenci Döşkaya, Meltem Taşbakan, Hüsnü Pullukçu, Ercüment Karasulu, Şaban Tekin, and Mert Döşkaya

Subjects
SARS-CoV-2, DNA vaccine, K18-hACE2 transgenic mice, Large-scale production, Upstream, Downstream, Medicine, Science
Abstract

Abstract Severe acute respiratory syndrome coronavirus 2 had devastating consequences for human health. Despite the introduction of several vaccines, COVID-19 continues to pose a serious health risk due to emerging variants of concern. DNA vaccines gained importance during the pandemic due to their advantages such as induction of both arms of immune response, rapid development, stability, and safety profiles. Here, we report the immunogenicity and protective efficacy of a DNA vaccine encoding spike protein with D614G mutation (named pcoSpikeD614G) and define a large-scale production process. According to the in vitro studies, pcoSpikeD614G expressed abundant spike protein in HEK293T cells. After the administration of pcoSpikeD614G to BALB/c mice through intramuscular (IM) route and intradermal route using an electroporation device (ID + EP), it induced high level of anti-S1 IgG and neutralizing antibodies (P

Published
2024
Full Text
View/download PDF

2. Process development for an effective COVID-19 vaccine candidate harboring recombinant SARS-CoV-2 delta plus receptor binding domain produced by Pichia pastoris

Author

Sibel Kalyoncu, Semiramis Yilmaz, Ayca Zeybek Kuyucu, Dogu Sayili, Olcay Mert, Hakan Soyturk, Seyda Gullu, Huseyin Akinturk, Erhan Citak, Merve Arslan, Melda Guray Taskinarda, Ibrahim Oguzhan Tarman, Gizem Yilmazer Altun, Ceren Ozer, Ridvan Orkut, Aysegul Demirtas, Idil Tilmensagir, Umur Keles, Ceren Ulker, Gizem Aralan, Yavuz Mercan, Muge Ozkan, Hasan Onur Caglar, Gizem Arik, Mehmet Can Ucar, Muzaffer Yildirim, Tugce Canavar Yildirim, Dilara Karadag, Erhan Bal, Aybike Erdogan, Serif Senturk, Serdar Uzar, Hakan Enul, Cumhur Adiay, Fahriye Sarac, Arzu Tas Ekiz, Irem Abaci, Ozge Aksoy, Hivda Ulbegi Polat, Saban Tekin, Stefan Dimitrov, Aykut Ozkul, Gerhard Wingender, Ihsan Gursel, Mehmet Ozturk, and Mehmet Inan

Subjects
Medicine, Science
Abstract

Abstract Recombinant protein-based SARS-CoV-2 vaccines are needed to fill the vaccine equity gap. Because protein-subunit based vaccines are easier and cheaper to produce and do not require special storage/transportation conditions, they are suitable for low-/middle-income countries. Here, we report our vaccine development studies with the receptor binding domain of the SARS-CoV-2 Delta Plus strain (RBD-DP) which caused increased hospitalizations compared to other variants. First, we expressed RBD-DP in the Pichia pastoris yeast system and upscaled it to a 5-L fermenter for production. After three-step purification, we obtained RBD-DP with > 95% purity from a protein yield of > 1 g/L of supernatant. Several biophysical and biochemical characterizations were performed to confirm its identity, stability, and functionality. Then, it was formulated in different contents with Alum and CpG for mice immunization. After three doses of immunization, IgG titers from sera reached to > 106 and most importantly it showed high T-cell responses which are required for an effective vaccine to prevent severe COVID-19 disease. A live neutralization test was performed with both the Wuhan strain (B.1.1.7) and Delta strain (B.1.617.2) and it showed high neutralization antibody content for both strains. A challenge study with SARS-CoV-2 infected K18-hACE2 transgenic mice showed good immunoprotective activity with no viruses in the lungs and no lung inflammation for all immunized mice.

Published
2023
Full Text
View/download PDF

3. Detection of neutralising antibodies against SARS-CoV-2 in companion animals in Istanbul

Author

Hakan ENÜL, Fahriye SARAÇ, Cumhur ADIAY, Serdar UZAR, Pelin TUNCER-GÖKTUNA, Seçkin Serdar ARUN, and Mustafa HASÖKSÜZ

Subjects
Veterinary, SARS-CoV-2, COVID-19, Neutralising antibodies, cat, dog, Veteriner Hekimlik
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and rapidly spread throughout the world. After the susceptibility of various animals to SARS-CoV-2 infection was reported, the prevalence of COVID-19 infection in pet animals and their role in virus transmission became a source of concern. Seroprevalence of SARS-CoV-2 in pet animals has been reported from various parts of the world to date. In this study, 206 serum samples of household dogs and cats were obtained from a diagnostic laboratory in Istanbul. Ninety-nine of the samples were collected during the second wave (November and December 2020) of the pandemic, and 107 were collected between August and September 2021. Neutralizing antibodies against SARS-CoV-2 in companion animals was investigated by virus neutralization test. Among the 99 serum samples which were collected during the second wave (November and December 2020) of the pandemic, while no neutralizing antibodies were found in 61 sera of cats, one of 38 dogs was positive with a titer of 1/256. Similarly, 0/54 cats and 1/53 dogs were tested positive for the neutralizing antibodies among the samples collected between August and September 2021. This study is demonstrating the evidence of SARS-CoV-2 infection in dogs.

Published
2022

4. Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection

Author

Gulay Korukluoglu, İlayda Baydemir, Tugce Yildirim, Muzaffer Yildirim, Irem Evcili, Sefa Burak Cam, Ismail Selim Yildirim, Nese Guvencli, Ihsan Gursel, Naz Surucu Yilmaz, Yasemin Ceylan, İsmail Cem Yılmaz, Osman Erganiş, Basak Kayaoglu, Yagmur Aydin, Mayda Gursel, Hakan Enul, Emre Mert İpekoğlu, Fahriye Sarac, Asli Gulce Bartan, Merve Gizer, Gamze Aykut, Cumhur Adiay, Hasan Ersin Zeytin, Petek Korkusuz, Bilgi Gungor, Eda Çiftci Dede, Hivda Polat, Ihsan Cihan Ayanoglu, Şaban Tekin, Tugce Bildik, Berfu Saraydar, Hatice Asena Sanli, Nilsu Turay, Irem Abras, Artun Bulbul, Bilgehan Ibibik, Serdar Uzar, Yılmaz, İsmail Cem, Bülbül, Artun, Turay, Nilsu, Yıldırım, Muzaffer, Evcili, İrem, Güngör, Bilgi, Saraydar, Berfu, Bartan, Aslı Gülce, İbibik, Bilgehan, Bildik, Tuğçe, Ceylan, Yasemin, Yıldırım, Tuğçe, Abraş, İrem, Aykut, Gamze, and Gürsel, İhsan

Subjects
COVID-19 Vaccines, viruses, Immunology, Antibodies, Viral, complex mixtures, SARS‐CoV‐2, Immune system, Virus-like particle, Antigen, COVID‐19, vaccine, Immunology and Allergy, Animals, Humans, Vaccines, Virus-Like Particle, SARS-CoV-2, Immunogenicity, HEK 293 cells, fungi, virus diseases, COVID-19, Transfection, biochemical phenomena, metabolism, and nutrition, Virology, Antibodies, Neutralizing, Vaccination, HEK293 Cells, Allergen‐Specific Immunotherapy and Biologics, Humoral immunity, Original Article, ORIGINAL ARTICLES, Covid-19, Vaccine, virus‐like particle, CpG ODN Adjuvant
Abstract

Background Vaccines that incorporate multiple SARS‐CoV‐2 antigens can further broaden the breadth of virus‐specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2. Methods VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable‐resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Results Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS‐CoV‐2. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicited high titer anti‐S, anti‐RBD, anti‐N IgG, triggered multifunctional Th1‐biased T‐cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals. Conclusion These data suggest that VLPs expressing all four structural protein antigens of SARS‐CoV‐2 are immunogenic and can protect animals from developing COVID‐19 infection following vaccination., SARS‐CoV‐2 VLP vaccine that incorporates the four structural proteins of SARS‐CoV‐2 is reproducibly produced in suspension adapted HEK293 cells. Alum adsorbed, K3‐CpG ODN‐adjuvanted VLPs elicit high titer anti‐S, anti‐RBD, anti‐N IgG, and neutralizing antibodies in mice, rats, and ferrets. The VLP vaccine supports multifunctional Th1‐biased T‐cell responses and demonstrate immunoprotective activity against live SARS‐CoV‐2 challenge in vaccinated mice.

Published
2021

5. Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 Infection

Author

Ismail Selim Yildirim, Cumhur Adiay, Şaban Tekin, Hakan Enul, Eda Çiftci Dede, Muzaffer Yildirim, Serdar Uzar, Bilgehan Ibibik, Sefa Burak Cam, Tugce Yildirim, Emre Mert İpekoğlu, Nilsu Turay, Tugce Bildik, Artun Bulbul, Asli Gulce Bartan, Mayda Gursel, Hatice Asena Sanli, Ihsan Gursel, Naz Surucu Yilmaz, Irem Abras, Fahriye Sarac, Ismail Yilmaz C, Berfu Saraydar, Bilgi Gungor, Hivda Polat, Yasemin Ceylan, Basak Kayaoglu, Ihsan Cihan Ayanoglu, Irem Evcili, Osman Erganiş, Nese Guvencli, Yagmur Aydin, Merve Gizer, Gamze Aykut, Hasan Ersin Zeytin, İlayda Baydemir, and Petek Korkusuz

Subjects
Chemistry, viruses, Immunogenicity, T cell, fungi, virus diseases, Transfection, biochemical phenomena, metabolism, and nutrition, complex mixtures, Virology, Vaccination, Immune system, medicine.anatomical_structure, Antigen, Virus-like particle, Humoral immunity, medicine
Abstract

Background Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the 4 structural proteins of SARS-CoV-2. Methods VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography and characterized by tunable resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Results Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1 biased T cell responses, reduced virus load and prevented lung pathology upon live virus challenge in vaccinated animals. Conclusion These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.

Published
2021
Full Text
View/download PDF

6. Development and Preclinical Evaluation of Virus Like Particle Vaccine Against COVID-19 Infection

Author

Ismail Yilmaz C, Emre Ipekoglu, Muzaffer Yildirim, Irem Evcili, Naz Yilmaz, Artun Bulbul, Nilsu Turay, Yagmur Aydin, Nese Guvencli, Bilgi Gungor, Berfu Saraydar, Asli Gulce Bartan, Bilgehan Ibibik, Tugce Bildik, İlayda Baydemir, Sefa Burak Cam, Eda Ciftci Dede, Merve Gizer, Osman Erganis, Fahriye Sarac, Serdar Uzar, Hakan Enul, Cumhur Adiay, Gamze Aykut, Hivda Polat, Saban Tekin, Hasan E. Zeytin, Petek Korkusuz, Ihsan Gursel, and Mayda Gursel

Subjects
viruses, fungi, virus diseases, biochemical phenomena, metabolism, and nutrition, complex mixtures
Abstract

Background Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the 4 structural proteins of SARS-CoV-2. Methods VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography and characterized by tunable resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Results Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1 biased T cell responses, reduced virus load and prevented lung pathology upon live virus challenge in vaccinated animals. Conclusion These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results